Accellena Research & Development is a leading provider of clinical and non-clinical research services, dedicated to advancing healthcare through a robust evidence-based approach. Established in 2005, the company has made significant strides in drug trials, successfully conducting over 70 clinical studies across Eastern Europe and Asia, with more than 15,000 subjects participating to date. Accellena specializes in human pharmacology, data science, and real-world data analytics, offering comprehensive support for early and late-phase clinical trials, including landmark vaccine studies for diseases like influenza and MERS.

Their in-house expertise encompasses data management and evidence generation, ensuring precision and reliability in every research initiative. With a commitment to innovation, Accellena deploys advanced methodologies and technologies for effective study designs, fostering a transparent and collaborative research environment. The company's mission transcends borders, aiming to provide cutting-edge treatments and preventative measures for critical health issues as they continue to explore the intersection of medical science and public health.